Introduction {#s1}
============

Among cancer patients, understanding the frequency and risk factors for acute kidney injury (AKI) after IV contrast (CON) is particularly important since these patients rely on imaging studies with CON for diagnosis and staging of disease, to monitor response to treatment, and for surveillance for disease recurrence. There are few studies on AKI after CON in cancer patients. The majority of these reports are small and limited to critical care or Emergency Room populations \[[@b1], [@b2], [@b3]\]. Current data from noncancer cohorts suggests that lower estimated glomerular filtration rate (eGFRs), independent of CON, is the major risk factor for AKI. On the other hand, a recent observational study in a cancer cohort suggests that CON is indeed an independent risk factor for AKI \[[@b4]\]. This raises the possibility that AKI after CON may have different pathogeneses and frequencies among cancer and noncancer patients.

Clinical and epidemiological studies suggest that dysregulation of inflammatory responses plays a role in the genesis and promotion of cancer growth \[[@b5]\]. Some of the same proinflammatory molecules involved in tumor-cell proliferation, transformation, and invasion have been implicated in the pathogenesis of AKI after CON. These include endothelin, reactive oxygen species, and hypoxia-inducible factor 1α \[[@b6], [@b7], [@b8], [@b9], [@b10], [@b11]\]. The available evidence suggests that cancer patients may have a higher rate of AKI from all causes. The odds ratio (OR) for AKI from all causes in cancer patients as compared to noncancer patients is 1.79 \[[@b12]\], and the reported 1- and 5-year risks for AKI in cancer patients are 17.5% and 27%, respectively, with corresponding risks of 6.7% and 18.6% in noncancer patients \[[@b13]\]. Whether cancer patients also have a higher rate of AKI after CON has not yet been investigated in a large cohort.

To examine this, we designed a study to determine: (1) the rates of AKI after CON and noncontrast (NC) CT scans in cancer inpatients, (2) whether the rates of AKI differed among cancer subtypes, and (3) whether recent chemotherapy, comorbid conditions, or nephrotoxins are associated with AKI.

Material and methods {#s2}
====================

After obtaining approval from the Institutional Review Board at Memorial Sloan Kettering Cancer, retrospective data was obtained from January 1, 2012 to December 30, 2014 on patients ≥ 18 years of age who had a CON or NC CT of the head, neck, or chest and who had a serum creatinine (SCr) within 3 days before and after CT. Because CT of the abdomen and pelvis are usually ordered with CON "by default", and when they are not, the physician's decision to not administer contrast may be influenced by the patient's SCr, these studies were excluded to decrease bias. The same volume of CON is given for all CON CT scans. The dose of omnipaque300 (General Electric Healthcare, Princeton, NJ, USA) given for a SCr \< 2 mg/dL is 75 -- 100 cc. For a SCr ≥ 2 mg/dL, IV contrast is usually not given, and if it is, it is usually in consultation with a nephrologist. Exclusion criteria were: a CON CT ≤ 3 days before a NC CT, patients on either acute or chronic renal replacement therapy, and no matched pre- and post-CT SCr. If \> 1 NC or CON CT was done on the same date, these were counted as one study. AKI was defined using the Kidney Disease Improving Global Outcomes criteria (increase in SCr 1.5× baseline). Urine output criteria were not used to define AKI. The baseline SCr was defined as the maximum SCr within 3 days prior to the CT scan. The eGFR was calculated using the 4-variable Modification of Diet in Renal Disease (MDRD) formula. International Statistical Classification of Diseases codes (ICD-9) were used to identify diagnoses and medications previously identified as risk factors for contrast-induced nephropathy (multiple myeloma (MM), diabetes mellitus (DM) congestive heart failure (CHF), hypotension, liver metastases, any chemotherapy given ≤ 60 days prior to CT, chronic kidney disease (CKD), nonsteroidal anti-inflammatory medications (NSAIDs), cyclooxygenase 2 inhibitors (COX2), angiotensin converting enzyme inhibitors (ACE I), angiotensin II receptor blockers (A2RB), vascular endothelial growth factor inhibitors (anti-VEGF), immune checkpoint inhibitors, tyrosine kinase inhibitors (TKI), gemcitabine, and cisplatin). Protected health information was coded in accordance with the requirements of the Health Insurance Portability and Accountability Act.

Statistical methods {#sub-s1}
-------------------

Associations between categorical variables, including AKI, CON/NC, patient characteristics, and other clinical variables were examined using the Rao-Scott χ^2^-test, considering that some patients had multiple scans during the study period. The continuous baseline eGFR was compared between patients with CON and NC as well as between patients with and without AKI, using generalized linear regressions with logit link function, and generalized estimating equations (GEE) with a robust covariance matrix and the exchangeable correlation structure, to take into account multiple scans in some patients. In a multivariable analysis, a generalized linear regression and the GEE method were used to assess associations between AKI and CON, controlling for other clinical factors univariately associated with AKI. Backward selection was used with a significance level at 0.05. OR of each covariate along with the 95% confidence interval were estimated in univariate and multivariable models.

Propensity score matching was performed as a sensitivity analysis to minimize the confounding effects in this retrospective study. The propensity score was first calculated based on all variables univariately associated with CON. A 1:1 matching was then applied on propensity score allowing for a matching distance of 20% of the standard deviation. We reported standardized mean differences between CON and NC groups as a measure of balance in the matched data. The association between CON and the risk of AKI was examined using a conditional logistic regression.

A test with p-value \< 0.05 was considered statistically significant in our analyses. All statistical analyses were performed in software packages SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and The R version 3.4 (R Foundation for Statistical Computing, Vienna, Austria).

Results {#s3}
=======

A total of 7,512 CT scans were performed in 4,456 patients. There were 4,958 NC and 2,554 CON CT scans. Demographic data is shown in [Table 1](#Table1){ref-type="table"}. The rate of AKI after CON was 7.3% and 11.4% in the NC group (p \< 0.001). In both groups, AKI was associated with lower baseline eGFRs ([Table 2](#Table2){ref-type="table"}). AKI rates at eGFRs ≤ 29 mL/min/1.73m^2^, 30 -- 59 mL/min/1.73m^2^, and ≥ 60 mL/min/1.73m^2^ were 26.3%, 18%, and 7.5% in all scans; 13.3%, 11.5%, and 6.7% in the CON group and 26.9%, 20%, and 7.9% in the NC group, respectively. CON was ordered less frequently at lower eGFRs (4.4% at ≤ 29 mL/min/1.73m^2^, and 37.9% at ≥ 60 mL/min/1.73m^2^, p \< 0.001).

The initial observations are shown in [Table 3](#Table3){ref-type="table"}. Significantly higher rates of AKI were observed in those treated with TKI/anti-VEGF, (p = 0.01), any chemotherapy within 60 days, CHF, CKD, AKI, brain and other nervous system tumors, leukemia, lymphoma, male genital system, myeloma, oral cavity and pharynx tumors, respiratory system tumors (all p \< 0.001), digestive system and female genital system tumors (all p = 0.01).

In multivariate analysis ([Table 4](#Table4){ref-type="table"}) controlling for contrast, chemotherapy within 60 days (OR = 1.22, p = 0.02), CHF (OR = 1.51, p = 0.0006), prior AKI (OR = 3.89, p ≤ 0.0001), and lower eGFRs remained significant risk factors for AKI. The risk of AKI increased with lower baseline eGFR: for eGFR ≤ 29 mL/min/1.73m^2^, OR = 1.83 (p = 0.0002); for eGFR 30 -- 59 mL/min/1.73m^2^, OR = 1.5 compared to eGFR ≥ 60 mL/min/1.73m^2^ (p \< 0.0001). The risk of AKI was not different between CON and NC scans (OR = 1.08, 95% CI: 0.90 -- 1.29, p = 0.42). None of the medications traditionally associated with AKI (NSAIDs, ACE I, A2RB) were found to be significantly associated with AKI. The rate of AKI for patients with history of DM, CKD, or hypotension was not different between the two groups. No cancer subtype was associated with a higher OR for AKI.

To minimize confounding effects on contrast, we matched 2,257 pairs of CON and NC samples in 1:1 propensity score matching analysis. All variables were balanced in two sample groups ([Table 5](#Table5){ref-type="table"}). The OR for AKI with contrast was 0.87 (95% CI: 0.87 -- 1.09, p = 0.23). Realizing that the absolute numbers of patients in the propensity model at lower eGFRs were quite small and that it may be more meaningful to look at patients with a clearly abnormal creatinine at baseline or an eGFR \< 45 mL/min/1.73m^2^, we performed multivariate analysis to look for associations with AKI in patients with eGFR \< 45 mL/min/1.73m^2^. The multivariate analysis showed that the OR for AKI was still higher in the NC group, although not significant (OR 1.58, p = 0.17).

Discussion {#s4}
==========

Recent large retrospective data base analyses in noncancer patients have brought into question whether contrast-induced nephropathy even exists, given that the reported rates of AKI following CON are similar to the basal rate of AKI observed in hospitalized patients \[[@b14], [@b15]\]. It has been assumed that the results from noncancer cohorts can be generalized to cancer patients. However, this population may have unique risk factors for AKI after CON, including exposure to tumoral cytokines, nephrotoxic chemotherapy, and complications from cancer treatment. This study reports the rate and risk factors for AKI after NC and CON CT scans in the largest cancer cohort examined so far. Unlike previous investigations, we did not exclude patients with low SCr values, and the AKI rate was measured using calculated eGFR as opposed to relying on ICD-9 coding. Consequently, we believe our study provides a better assessment of AKI after CT in a general cancer cohort.

The rate of AKI after CON was 7.3%, significantly lower than the rate of AKI observed in patients who did not receive CON. Akin to data in noncancer cohorts \[[@b16], [@b17], [@b18]\], our analysis showed that AKI was significantly associated with overall lower baseline eGFR, independent of contrast exposure. Because there are ethical constraints to performing a randomized case control trial to examine the relationship between AKI and CON, especially at lower eGFRs, we used propensity score matching method to reach a 1:1 match in the CON and NC groups using all the variables that were associated with contrast. The propensity analysis showed a trend towards a lower rate of AKI in the CON group, but this did not reach statistical significance. In summary, none of the statistical models used in this analysis demonstrated a higher rate of AKI from CON exposure in cancer patients.

Methodological issues make it difficult to make comparisons between findings from our study and those from studies done elsewhere in both cancer and noncancer cohorts. Our results do not support our supposition that the proinflammatory milieu of cancer results in an increased rate of AKI after CON. The observed rate of 7.3% is within the range of AKI after CON reported in noncancer cohorts \[[@b19]\]. Prior studies have reported higher rates of AKI in cancer patients after CON, ranging from 8 to 20% \[[@b1], [@b2], [@b3], [@b20]\]. However, these were smaller studies.

The finding of a lower rate of AKI after CON exposure does not support any protective effect from its use, nor does it support the liberalization of current institution-specific or American College of Radiology screening guidelines \[[@b21]\] for prevention of contrast-induced nephropathy in patients with eGFRs ≤ 59 mL/min/1.73m^2^. While we tried to overcome some of the limitations inherent in analyses of retrospective data by utilizing propensity score modeling, the higher observed rate of AKI in the NC group in this report highlights a major limitation of retrospective data analysis. We were unable to ascertain whether patients with lower eGFRs received IV hydration with CON studies. Additionally, our data suggests that physicians may preferentially be ordering NC studies in patients with eGFRs ≤ 29 mL/min/1.73m^2^. In over 95% of cases, the physician ordered a NC CT for patients at this eGFR level. While our multivariate analysis showed that when controlling for comorbidities like prior AKI, CHF, and hypotension, the risk of AKI was not different between the CON and NC groups (p = 0.35), the possibility remains that clinical information that cannot be adequately captured from a retrospective data query played a role in the physicians' decision to order a NC or a CON CT scan.

Several groups of patients experienced significantly higher overall rates of AKI. One important and unique observation to cancer patients is that receiving any chemotherapy within ≤ 60 days of a CON study was associated with an increased risk for AKI. This observation has been made in other cancer cohorts \[[@b2], [@b4]\]. Therefore, patients on active or recent chemotherapy may require extra care and caution when ordering CON studies. Possible explanations for this finding include: (1) pre-existing prerenal azotemia or ischemic acute tubular necrosis from nausea, vomiting, and diarrhea; 2) direct nephrotoxicity of the cancer drugs and/or; 3) other nephrotoxic complications from treatment (tumor lysis syndrome, hypercalcemia). We found no correlation with any specific group of anticancer agent and AKI. As compared to previous observations \[[@b4]\], AKI rates were not significantly higher among patients with hematologic malignancies compared to those with solid tumors.

A limitation of this and of all retrospective studies that have examined the relationship between AKI and CON is the relatively small number of patients with eGFRs ≤ 29 mL/min/1.73m^2^ who receive IV contrast. We used propensity score method to account for potentially-confounding variables, but these patients still accounted for \< 1% of all CT studies. Limiting our data set to only those who had a CT of the head, neck, and chest did decrease the number of evaluable subjects, but since all contrast studies receive the same volume of contrast, this should not have significantly impacted the observations made. Future prospective studies utilizing a broader cancer cohort may still add new information to our current understanding of AKI after CON.

Conclusion {#s5}
==========

This is the largest retrospective study to date that has examined the rate of AKI after NC and CON CT scans in a cancer cohort at a comprehensive cancer center. AKI was significantly associated with lower baseline eGFRs, independent of contrast exposure. Additional risk factors for AKI in cancer patients were the administration of chemotherapy within ≤ 60 days of CT, CHF, and prior AKI. The observed rate of AKI after IV contrast in a large cancer cohort was not appreciably different from prior reports on noncancer cohorts.
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Table 1.Patient characteristics at baseline.All scansNoncontrastContrastGender   Female3,451 (45.94%)2,151 (43.38%)1,300 (50.9%)   Male4,061 (54.06%)2,807 (56.62%)1,254 (49.1%)Race   Asian519 (6.83%)347 (7%)172 (6.73%)   Black677 (9.01%)444 (8.96%)233 (9.12%)   Native American7 (0.09%)5 (0.1%)2 (0.08%)   White6,309 (83.99%)4,162 (83.95%)2,147 (84.06%)Ethnicity   Hispanic or Latino370 (4.93%)240 (4.84%)130 (5.09%)   No value entered1 (0.01%)0 (0%)1 (0.04%)   Not Hispanic or Latino7,141 (95.06%)4,718 (95.16%)2,423 (94.87%)Malignancy type   Bones and joints139 (1.9%)72 (1.5%)67 (2.6%)   Brain and other nervous system490 (6.5%)388 (7.8%)102 (4%)   Breast471 (6.3%)255 (5.1%)216 (8.5%)   Digestive system1,006 (13.4%)511 (10.3%)495 (19.4%)   Endocrine system181 (2.4%)103 (2.1%)78 (3.1%)   Eye and orbit24 (0.3%)15 (0.3%)9 (0.4%)   Female genital system387 (5.2%)130 (2.6%)257 (10.1%)   Leukemia2,033 (27.1%)1,680 (33.9%)353 (13.8%)   Lymphoma1,620 (21.6%)1,254 (25.3%)366 (14.3%)   Male genital system467 (6.2%)311 (6.3%)156 (6.1%)   Myeloma425 (5.7%)355 (7.2%)70 (2.7%)   Oral cavity and pharynx231 (3.1%)88 (1.8%)143 (5.6%)   Respiratory system1,073 (14.3%)561 (11.3%)512 (20%)   Skin excluding basal and squamous405 (5.4%)291 (5.9%)114 (4.5%)   Soft tissue including heart281 (3.7%)144 (2.9%)137 (5.4%)   Urinary system400 (5.3%)244 (4.9%)156 (6.1%)   Miscellaneous4,012 (53.4%)2,162 (43.6%)1,850 (72.4%)

Table 2.Associations between age, gender, and eGFR with AKI and contrast.All scan (N = 7,513)No AKI (n = 6,761)AKI (n = 751)p-valueAKI in noncontrast (N = 565)AKI in contrast (N = 186)p-valueBaseline eGFR, mean (SD) mL/min/1.73m^2^96.6 (47.6)98.3 (46.4)81.4 (55.0)\< 0.00172.6 (48.9)108.1 (63.5)\< 0.001CKD group\< 0.001\< 0.001   eGFR ≤ 29 mL/min/1.73m^2^342 (4.6%)252 (73.7%)90 (26.3%)88 (97.8%)2 (2.2%)   eGFR 30 -- 59 mL/min/1.73m^2^1,181 (15.7%)968 (82%)213 (18%)182 (85.4%)31 (14.6%)   eGFR ≥ 60 mL/min/1.73m^2^5,989 (79.7%)5,541 (92.5%)448 (7.5%)295 (65.8%)153 (34.2%)Age at CT, years0.010.34   18 -- 441,155 (15.4%)1,055 (91.3%)100 (8.7%)74 (74%)26 (26%)   45 -- 643,048 (40.6%)2,755 (90.4%)293 (9.6%)224 (76.5%)69 (23.5%)   65 and above3,309 (44%)2,951 (89.2%)358 (10.8%)267 (74.6%)91 (25.4%)Gender\< 0.001\< 0.001   Female3,451 (45.9%)3,153 (91.4%)298 (8.6%)211 (70.8%)87 (29.2%)   Male4,061 (54.1%)3,608 (88.8%)453 (11.2%)354 (78.1%)99 (21.9%)Contrast\< 0.001   No4,958 (66%)4,393 (88.6%)565 (11.4%)   Yes2,554 (34%)2,368 (92.7%)186 (7.3%)[^1]

Table 3.AKI by patient clinical factors at time of scan.FactorAKI (%)No AKI (%)p-valueMutation status   Any mutation79 (10.5%)793 (11.7%)0.12   TKI/VEGF inhibitors19 (2.5%)261 (3.9%)0.01   Immune checkpoint/BRAF/EGFR inhibitors19 (2.5%)171 (2.5%)0.99Chemotherapy within 60 days of CT scan   Any chemotherapy478 (63.6%)3,769 (55.7%)\< 0.001   Bisphosphonates1 (0.1%)8 (0.1%)0.92   Gemcitabine27 (3.6%)275 (4.1%)0.31   Cisplatin24 (3.2%)177 (2.6%)0.19Medication   ACE inhibitors109 (14.5%)1,063 (15.7%)0.25   Angiotensin Receptor Blocker69 (9.2%)587 (8.7%)0.49   NSAIDs and COX2 inhibitor38 (5.1%)458 (6.8%)0.02Comorbid disease   Diabetes mellitus207 (27.6%)1,707 (25.2%)0.07   Congestive heart failure151 (20.1%)684 (10.1%)\< 0.001   Hypotension119 (15.8%)1,131 (16.7%)0.46   Liver metastasis96 (12.8%)1,208 (17.9%)\< 0.001   Chronic kidney disease216 (28.8%)893 (13.2%)\< 0.001   Acute kidney injury510 (67.9%)2,001 (29.6%)\< 0.001Malignancy type   Bones and joints16 (2.1%)123 (1.8%)0.44   Brain and other nervous system20 (2.7%)470 (7%)\< 0.001   Breast38 (5.1%)433 (6.4%)0.03   Digestive system87 (11.6%)919 (13.6%)0.01   Endocrine system13 (1.7%)168 (2.5%)0.07   Eye and orbit2 (0.3%)22 (0.3%)0.79   Female genital system, in females29 (3.9%)358 (5.3%)0.01   Leukemia265 (35.3%)1,768 (26.1%)\< 0.001   Lymphoma202 (26.9%)1,418 (21%)\< 0.001   Male genital system, in males63 (8.4%)404 (6%)\< 0.001   Myeloma68 (9.1%)357 (5.3%)\< 0.001   Oral cavity and pharynx13 (1.7%)218 (3.2%)\< 0.001   Respiratory system84 (11.2%)989 (14.6%)\< 0.001   Skin excluding basal and squamous49 (6.5%)356 (5.3%)0.04   Soft tissue including heart26 (3.5%)255 (3.8%)0.45   Urinary system45 (6%)355 (5.3%)0.12[^2]

Table 4.Regression analysis on AKI in all scans.Univariate analysisMultivariable analysisOR of AKI (95%CI)OR of AKI (95%CI)p-valueNoncontrast (ref= contrast)1.6 (1.34, 1.89)1.08 (0.9, 1.29)0.424Baseline eGFR   ≤ 29 mL/min/1.73m^2^4.01 (2.96, 5.43)1.83 (1.33, 2.52)0.001   30 -- 59 mL/min/1.73m^2^2.59 (2.13, 3.14)1.5 (1.23, 1.84)\< 0.001   ≥ 60 mL/min/1.73m^2^ (ref)Any chemotherapy1.38 (1.17, 1.63)1.22 (1.03, 1.45)0.021Brain and other nervous system malignancy0.35 (0.21, 0.61)0.57 (0.33, 0.96)0.036Congestive heart failure2.32 (1.86, 2.89)1.51 (1.19, 1.91)0.001Prior acute kidney injury5.13 (4.32, 6.1)3.89 (3.2, 4.73)\< 0.001[^3]

Table 5.Summary of propensity score-matched data.Noncontrast\
(n = 2,252)Contrast\
(n = 2,252)Standardized mean differenceVariance ratioGFR group ( mL/min/1.73m^2^)   GFR ≤ 2917 (0.8%)15 (0.7%)Reference   GFR 30 -- 59273 (12.1%)269 (11.9%)--0.550.99   GFR ≥ 601962 (87.1%)1,968 (87.4%)0.80.98Gender, male1174 (52.1%)1,154 (51.2%)--1.781Age (years)   18 -- 44305 (13.5%)322 (14.3%)Reference   45 -- 64897 (39.8%)915 (40.6%)1.631.01   65 and above1,050 (46.6%)1,015 (45.1%)--3.120.99NSAIDs and COX2 inhibitors171 (7.6%)166 (7.4%)--0.850.97TKI and VEGF92 (4.1%)90 (4%)--0.450.98Any chemotherapy \< 60 days1,152 (51.2%)1,172 (52%)1.781Tumor type   Brain and other nervous system96 (4.3%)102 (4.5%)1.281.06   Leukemia, lymphoma, and multiple myeloma608 (27%)610 (27.1%)0.21   Genital316 (14%)304 (13.5%)--1.560.97   Oral cavity and pharynx76 (3.4%)96 (4.3%)4.41.25   Respiratory system427 (19%)425 (18.9%)--0.231   Digestive system403 (17.9%)404 (17.9%)0.121   Skin excluding basal and squamous114 (5.1%)114 (5.1%)01Comorbidities   Diabetes mellitus561 (24.9%)548 (24.3%)--1.340.98   Congestive heart failure209 (9.3%)207 (9.2%)--0.310.99   Hypotension306 (13.6%)315 (14%)1.151.02   Liver metastasis532 (23.6%)534 (23.7%)0.211   Chronic kidney disease186 (8.3%)185 (8.2%)--0.161   Acute kidney injury538 (23.9%)529 (23.5%)--0.940.99[^4]

[^1]: CKD = chronic kidney disease; AKI = acute kidney injury; eGFR = estimated glomerular filtration rate.

[^2]: AKI = acute kidney injury; TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth factor; BRAF = B-RAF kinase inhibitor; EGFR inhibitors = epidermal growth factor inhibitor; ACE inhibitors = angiotensin converting enzyme inhibitor; NSAIDs = non-steroidal anti-inflammatory drugs; COX2 inhibitor = cyclo oxygenase 2 inhibitor.

[^3]: AKI = acute kidney injury; Ref = reference group; OR = odds ratio; eGFR = estimated glomerular filtration rate.

[^4]: CKD = chronic kidney disease; GFR = glomerular filtration rate; NSAIDs = non-steroidal anti-inflammatory drugs; COX2 inhibitors = cyclo oxygenase 2 inhibitors; TKI = tyrosine kinase inhibitor; VEGF = vascular endothelial growth factor.
